Additionally, while some studies raise concerns about GLP-1s increasing depression, anxiety, and suicidal thoughts, other studies point in the opposite direction, noting a decrease in depressive symptoms, improved cognitive function, and an increase in feelings of self-mastery
Diabetes and anxiety in US adults: findings from the 2006 behavioral risk factor surveillance system
Combining unregulated dietary supplements with prescription GLP-1 drugs could also pose potential health risks, especially for people with diabetes
In people with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg resulted in 20% reduction in major adverse cardiovascular events [(MACE), death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke] compared to placebo (SELECT trial) after a mean follow-up of 39.8 months this is the first trial demonstrating cardiovascular benefit for an obesity pharmacotherapy [110]